Topics Covered
- Omics technologies
- Technology platforms: (2DE-MS, LC-MS-MS, CE/MS)
- Clinical proteomics
- Precision as a function of no. of markers
- Human urinary LMW proteome database
- Requirements for biomarker selection
- How to identify valid proteomic biomarkers
- Effect size estimation and the number of samples
- Erroneous biomarkers
- Classification using different sizes of training sets
- Classification errors
- CKD biomarkers
- Biomarker validation
- Pathophysiological suggestions
- Selected urinary peptides and CKD staging
- Multicentric European PRIORITY trial
- Proteomics of coronary artery disease and of diabetic nephropathy
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Mischak, H. (2013, November 5). Urinary proteomics in kidney and cardiovascular disease [Video file]. In
The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved September 25, 2023, from
https://hstalks.com/bs/2678/.
Export Citation (RIS)
Publication History
-
Published on November 5, 2013
Financial Disclosures
- Prof. Harald Mischak, Stock Shareholder (Self-managed): Mosaiques Diagnostics.